Rapid resistance profiling of SARS-CoV-2 protease inhibitors.

Seyed Arad MoghadasiRayhan G BiswasDaniel A Harki Reuben Stewart Harris

Published in: bioRxiv : the preprint server for biology (2023)

Resistance to nirmatrelvir (Paxlovid) has been shown by multiple groups and may already exist in clinical SARS-CoV-2 isolates. Here a panel of SARS-CoV-2 main protease (M pro ) variants and a robust cell-based assay are used to compare the resistance profiles of nirmatrelvir, ensitrelvir, and FB2001. The results reveal distinct resistance mechanisms ("fingerprints") and indicate that these next-generation drugs have the potential to be effective against nirmatrelvir-resistant variants and vice versa .

Keyphrases

sars cov
respiratory syndrome coronavirus
single cell
copy number
risk assessment
climate change
bone marrow
drug induced